Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Novartis | Contract Pharma

What are you searching for?

Sign in
Breaking News, Promotions & Moves

Novartis

Author Image

By: Tim Wright

Editor-in-Chief, Contract Pharma

Novartis AG has promoted two senior U.S. executives to head its U.S. drugs unit and overall U.S. operations. Ludwig Hantson, head of Novartis’ specialty medicines unit in the U.S., has been promoted to chief executive of Novartis Pharmaceuticals Corp., the company’s North American drugs affiliate. He succeeds Alex Gorsky, who in February resigned to become chairman of the Ethicon surgical products division of Johnson & Johnson.
   
Mr. Hantson has previously run Novartis’ pharmaceutical operations in Canada and has been a senior company executive in Europe. Before joining the company in 2001, he spent 13 years as a senior executive for clinical development and marketing at the Jannsen pharmaceuticals unit of J&J.
   
Gary Rosenthal, chief financial officer of the company’s North American drugs unit, has been promoted to president and chief executive of Novartis Corp. He succeeds Paulo Costa, who plans to retire in late June.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters